Octapharma’s human plasma-derived von Willebrand Factor (VWF)/Factor VIII replacement product Wilate® has been granted expanded approval for prophylaxis by the U.S. Food and Drug Administration (FDA) to include all types of von Willebrand disease (VWD).
While the majority of women with von Willebrand disease (VWD) will experience heavy menstrual bleeding (HMB) often associated negative impacts on overall health and quality of life, available data relevant to effective treatment is limited.
The new VWD guidelines were published in 2020 and heavily integrate the patient voice. But how can you use these in your conversations with healthcare professionals? This session will take a deeper dive into the specific recommendations, where patients and healthcare professionals need to decide together on the best plan of care. You will learn essential skills in shared decision-making to advocate for the care you need.
NBDF provides free quality education on issues that matter to the bleeding disorders community. This video is on vwd: the realities of your period
NBDF provides free quality education on issues that matter to the bleeding disorders community. This video is on the basics of vwd
NBDF provides free quality education on issues that matter to the bleeding disorders community. This video is on the vwd guidelines: are they working for you
Takeda recently announced that the U.S. Food and Drug Administration (FDA) has approved VONVENDI® for routine prophylaxis to reduce the frequency of bleeding episodes in adults with severe Type 3 von Willebrand disease (VWD) receiving on-demand therapy.
CSL Behring announced that the company’s distribution agreement with Ferring Pharmaceuticals for STIMATE® nasal spray recently expired and will not be renewed effectively removing this medication as a valuable treatment opti
NHF's Wednesday Webinars for May 2021 will focus on Women's Health Month, featuring topics of interest to both patients and healthcare providers who are interested in issues faced by women with inheritable blood disorders.
The von Willebrand disease (VWD) pre-conference brings together the VWD community to connect in a lively, engaging and supportive educational environment. This year, we will focus on the elements of reconnecting, rebuilding and refocusing as a community. We will explore the many ways that we as a community can help raise awareness of VWD and help those who are unaware of their status. We’ll also discuss new medical updates and NHF’s course of action with VWD. Sponsored by CSL Behring.
2020 is the year that VWD guidelines will be announced. This will be an opportunity to learn, explore, and understand the new measures for treatment, diagnosis, and protocols.
A research abstract presented at the recent Thrombosis & Haemostasis Summit of North America 2020 Virtual Conference suggested that epidural analgesia may be a safe option for pregnant women with von Willebrand disease (VWD) type 1, provided clotting factors are maintained at certain levels.
